FOXP3 and cancer: Development in antisense oligonucleotide technology and RNA-targeting small molecules have proven that ncRNA is a ‘druggable’ molecule amenable for therapeutic treatment [29] and FOXP3 RNA has recently been reported to be a viable ASO target in a mouse cancer model [30].